Fusion peptide for treating autoimmune disease
AssigneeBeijing Zeqin Biomedical Co., Ltd
InventorsHuawei Wei, Chenggang Yang
Life of this patent
Estimating the term…
Abstract
PDL1-pHLIP, a preparation method of the PDL1-pHLIP, and an application of the PDL1-pHLIP in treatment of autoimmune diseases are provided. A fusion peptide is prepared by binding a pH low insertion peptide and an extracellular domain of PDL1. The pH low insertion peptide may be inserted onto a cell membrane of a focus tissue in an acid environment; the PDL1 bound to the pH low insertion peptide is subjected to targeting localization at the focus by utilizing the above properties of the pH low insertion peptide; a PD-1/PD-L1 negative signal of the focus tissue is enhanced by utilizing the pH low insertion peptide; and immune response of effector T cells is suppressed at the source, thereby achieving an effect of preventing and treating the autoimmune diseases.
Claims8
A fusion peptide of a pH low insertion peptide, comprising a pH low insertion peptide and an immune checkpoint ligand, wherein:
- the pH low insertion peptide comprises an extracellular domain sequence repeating by one or more times;
- the extracellular domain sequence consists of one of the amino acid sequences of SEQ ID NO:
- 1-17;
- the immune checkpoint ligand comprises an extracellular domain of the PD-L1;
- the extracellular domain of the PD-L1 comprises the amino acid sequence of SEQ ID NO:
- 18 or SEQ ID NO:
- 19;
- and
- the extracellular domain of the PD-L1 is bound to an N-terminus of the pH low insertion peptide through a linker.
Dependencies are inferred from the claim text.